Johnson & Johnson Appoints Larry Merlo as Non-Executive Chair Designate of Planned New Consumer Health Company

NEW BRUNSWICK, N.J., August 24, 2022– Johnson & Johnson (NYSE: JNJ) today announced the appointment of Larry Merlo as Non-executive Chair Designate for the future, listed New Consumer Health Company’s Board of Directors. Merlo previously served as President and CEO of CVS Health and brings over 30 years of purpose-driven and transformative health leadership to the Board for the planned new company. As announced in November 2021, the planned separation would create two global leaders – the new Johnson & Johnson and the New Consumer Health Company – both better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth. Today’s announcement follows the appointment of Thibaut Mongon as Chief Executive Officer Designate in May 2022. Merlo will formally assume the role as Non-executive Chair upon completion of the planned separation, expected to occur in 2023 subject to legal requirements including consultation with works councils and employee representatives, as required. Additional Directors will be determined and announced in the coming months as the planned separation process progresses.Alex Gorsky, Executive Chairman of Johnson & Johnson shared, “On behalf of the Board, I am pleased to welcome Larry as Chair Designate of the planned New Consumer Health Company. A purpose-driven leader, Larry’s experience in the fast-paced health retail sector will be a s...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news